Share Price and Basic Stock Data
Last Updated: December 18, 2025, 3:34 pm
| PEG Ratio | 0.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fermenta Biotech Ltd operates in the pharmaceutical sector, a field that has seen its share of volatility and opportunity. As of the latest reporting, the company’s share price stood at ₹265, with a market capitalization of ₹780 Cr. Over the past decade, Fermenta has navigated revenue fluctuations, with total sales reported at ₹528 Cr for the trailing twelve months (TTM). The revenue trend showcases a mixed performance; there was a notable decline in sales to ₹349 Cr in FY 2023 from ₹397 Cr in FY 2022, but a recovery is evident as the company reported ₹468 Cr for FY 2025. The quarterly sales figures also reveal some variability, with a peak at ₹156 Cr in December 2024 but a dip to ₹57 Cr in September 2023. This inconsistency may raise eyebrows regarding the company’s market positioning and operational stability, especially in a competitive landscape.
Profitability and Efficiency Metrics
Examining the profitability landscape, Fermenta Biotech’s operating profit margin (OPM) has shown significant fluctuation, reflecting operational challenges and cost management issues. The OPM dipped to a concerning 5% in FY 2023 and rebounded to 25% in FY 2025, indicating a potential turnaround in operational efficiency. The net profit margin also followed a similar trajectory, swinging from a loss of ₹53 Cr in FY 2023 to a profit of ₹76 Cr in FY 2025. Return on equity (ROE) stood at a robust 24.9%, which is commendable and suggests that the company is effectively generating returns for its shareholders. However, the cash conversion cycle (CCC) of 189 days might be a point of concern, indicating potential inefficiencies in managing receivables and inventory that could impact liquidity.
Balance Sheet Strength and Financial Ratios
From a balance sheet perspective, Fermenta appears reasonably strong, with total borrowings reported at ₹112 Cr against reserves of ₹376 Cr. This translates to a comfortable debt-to-equity ratio of 0.30, which is well within manageable limits for the industry. The interest coverage ratio (ICR) of 8.57x reflects a solid capacity to meet interest obligations, providing a safety net for investors. Additionally, the company’s price-to-book value (P/BV) ratio of 2.20x suggests that the stock is trading at a premium relative to its book value, which might indicate investor confidence in future growth prospects. However, the declining trend in total assets from ₹707 Cr in FY 2022 to ₹614 Cr in FY 2025 raises questions about asset utilization and the effectiveness of capital allocation.
Shareholding Pattern and Investor Confidence
The shareholding structure of Fermenta Biotech reveals a significant promoter holding of 64.08%, which indicates strong management control. However, foreign institutional investor (FII) participation is minimal at just 0.02%, suggesting a lack of broader market confidence or interest. The public shareholding has also seen a decline, dropping from 38.45% in December 2022 to 34.75% in September 2025. This trend might reflect a cautious sentiment among retail investors, potentially influenced by the company’s recent performance volatility. With 13,760 shareholders, the company has a diverse base, but the declining public stake could be a red flag for potential investors, as it may indicate waning interest in the stock.
Outlook, Risks, and Final Insight
Looking ahead, Fermenta Biotech’s journey seems poised for both opportunities and challenges. The strong ROE and improving profitability metrics provide a solid foundation for future growth. However, investors should remain vigilant regarding risks associated with revenue volatility and operational inefficiencies, particularly in managing working capital. The company’s ability to maintain its profitability margins while managing costs will be crucial. Additionally, the low FII interest may signal potential hurdles in gaining broader market acceptance. As an investor, evaluating Fermenta’s performance against industry benchmarks and keeping an eye on management’s strategies for growth and efficiency will be essential. The current market sentiment and operational dynamics will significantly influence the stock’s attractiveness in the coming periods.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 117 | 235/84.3 | 32.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,205 Cr. | 386 | 479/192 | 87.1 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.7 Cr. | 45.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 47.8 Cr. | 32.6 | 33.0/17.0 | 114 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,981.65 Cr | 1,143.16 | 52.24 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 98 | 55 | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 |
| Expenses | 87 | 95 | 65 | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 |
| Operating Profit | 5 | 3 | -10 | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 |
| OPM % | 5% | 3% | -18% | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% |
| Other Income | 4 | 3 | -19 | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 |
| Interest | 4 | 5 | 5 | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 |
| Depreciation | 7 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Profit before tax | -2 | -8 | -41 | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 |
| Tax % | 8% | 6% | -8% | 373% | 0% | 0% | 38% | 885% | 0% | 6% | 16% | -4% | 23% |
| Net Profit | -3 | -8 | -38 | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 |
| EPS in Rs | -0.88 | -2.75 | -12.70 | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 |
Last Updated: August 19, 2025, 3:45 pm
Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 136.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 136.00 Cr., marking a decrease of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 21.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from -4.00% (Mar 2025) to 23.00%, marking an increase of 27.00%.
- For Net Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.42. The value appears to be declining and may need further review. It has decreased from 11.68 (Mar 2025) to 7.42, marking a decrease of 4.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 563 |
| Expenses | 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 418 |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 145 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 26% |
| Other Income | 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 20 |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 23 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 130 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | |
| Net Profit | 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 111 |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 38.06 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -90.00% | 100.00% | -550.00% | 611.11% | 154.35% | -48.72% | -28.33% | -65.12% | -453.33% | 54.72% | 416.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 190.00% | -650.00% | 1161.11% | -456.76% | -203.07% | 20.38% | -36.78% | -388.22% | 508.05% | 361.95% |
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 7% |
| 3 Years: | 74% |
| TTM: | 532% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -3% |
| 3 Years: | 10% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 25% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 15 |
| Reserves | 130 | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 376 |
| Borrowings | 65 | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 112 |
| Other Liabilities | 61 | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 149 |
| Total Liabilities | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
| Fixed Assets | 87 | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 219 |
| CWIP | 36 | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 26 |
| Investments | 17 | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 118 | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 406 |
| Total Assets | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Reserves, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 348.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 112.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 115.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 149.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 219.00 Cr.. The value appears to be declining and may need further review. It has decreased from 227.00 Cr. (Mar 2025) to 219.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 372.00 Cr. (Mar 2025) to 406.00 Cr., marking an increase of 34.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears strong and on an upward trend. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
Notably, the Reserves (376.00 Cr.) exceed the Borrowings (112.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -39.00 | -55.00 | -68.00 | -75.00 | -80.00 | -53.00 | -158.00 | -149.00 | -177.00 | -202.00 | -111.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 |
| Working Capital Days | 9 | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.77 |
| Diluted EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.69 |
| Cash EPS (Rs.) | 34.50 | 0.24 | -8.77 | 14.08 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Revenue From Operations / Share (Rs.) | 160.95 | 116.25 | 121.27 | 138.15 | 130.79 |
| PBDIT / Share (Rs.) | 41.69 | 13.62 | 8.88 | 24.12 | 31.17 |
| PBIT / Share (Rs.) | 33.39 | 5.06 | -0.90 | 15.26 | 24.13 |
| PBT / Share (Rs.) | 28.53 | -3.42 | -17.98 | 9.34 | 17.90 |
| Net Profit / Share (Rs.) | 26.19 | -8.31 | -18.56 | 5.22 | 14.74 |
| NP After MI And SOA / Share (Rs.) | 26.35 | -7.99 | -17.85 | 5.35 | 15.77 |
| PBDIT Margin (%) | 25.90 | 11.71 | 7.32 | 17.46 | 23.83 |
| PBIT Margin (%) | 20.74 | 4.34 | -0.74 | 11.04 | 18.44 |
| PBT Margin (%) | 17.72 | -2.94 | -14.82 | 6.76 | 13.68 |
| Net Profit Margin (%) | 16.27 | -7.15 | -15.30 | 3.77 | 11.27 |
| NP After MI And SOA Margin (%) | 16.37 | -6.86 | -14.71 | 3.87 | 12.06 |
| Return on Networth / Equity (%) | 21.19 | -7.98 | -16.36 | 4.15 | 12.62 |
| Return on Capital Employeed (%) | 24.19 | 3.89 | -0.61 | 8.81 | 14.56 |
| Return On Assets (%) | 12.50 | -4.20 | -8.09 | 2.18 | 6.62 |
| Long Term Debt / Equity (X) | 0.04 | 0.14 | 0.26 | 0.30 | 0.30 |
| Total Debt / Equity (X) | 0.30 | 0.45 | 0.68 | 0.63 | 0.57 |
| Asset Turnover Ratio (%) | 0.80 | 0.56 | 0.52 | 0.55 | 0.57 |
| Current Ratio (X) | 1.58 | 1.40 | 1.21 | 1.52 | 1.48 |
| Quick Ratio (X) | 0.99 | 0.89 | 0.58 | 0.74 | 0.70 |
| Inventory Turnover Ratio (X) | 4.45 | 0.70 | 0.77 | 0.91 | 1.06 |
| Dividend Payout Ratio (NP) (%) | 4.69 | -15.65 | -7.00 | 46.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.57 | 217.49 | -15.50 | 17.58 | 0.00 |
| Earning Retention Ratio (%) | 95.31 | 115.65 | 107.00 | 53.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.43 | -117.49 | 115.50 | 82.42 | 0.00 |
| Interest Coverage Ratio (X) | 8.57 | 2.31 | 1.23 | 4.07 | 5.00 |
| Interest Coverage Ratio (Post Tax) (X) | 6.38 | 0.02 | -0.20 | 1.88 | 3.37 |
| Enterprise Value (Cr.) | 831.46 | 505.89 | 464.45 | 795.24 | 883.96 |
| EV / Net Operating Revenue (X) | 1.77 | 1.51 | 1.33 | 2.00 | 2.34 |
| EV / EBITDA (X) | 6.84 | 12.87 | 18.12 | 11.43 | 9.83 |
| MarketCap / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| Retention Ratios (%) | 95.30 | 115.65 | 107.00 | 53.31 | 0.00 |
| Price / BV (X) | 2.20 | 1.51 | 0.98 | 1.59 | 2.00 |
| Price / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| EarningsYield | 0.09 | -0.05 | -0.16 | 0.02 | 0.06 |
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
- For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
- For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
- For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
- For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
- For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.19. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.19, marking an increase of 29.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
- For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.45. This value is within the healthy range. It has increased from 0.70 (Mar 24) to 4.45, marking an increase of 3.75.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 4.69, marking an increase of 20.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 3.57, marking a decrease of 213.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.31. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.31, marking a decrease of 20.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.43. This value exceeds the healthy maximum of 70. It has increased from -117.49 (Mar 24) to 96.43, marking an increase of 213.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 831.46. It has increased from 505.89 (Mar 24) to 831.46, marking an increase of 325.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.77, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 6.84. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.84, marking a decrease of 6.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 95.30. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.30, marking a decrease of 20.35.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.20, marking an increase of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
- Net Profit Margin: 16.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.19% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.19% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 9.19 (Industry average Stock P/E: 42.98)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1501, Thane One, DIL Complex, Thane Maharashtra 400610 | info@fermentabiotech.com https://www.fermentabiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep M Chandan | Chairman & Ind.Dire (Non-Exe) |
| Mr. Krishna Datla | Exe.Vice Chairman & Whole Time Director |
| Mr. Prashant Nagre | Managing Director |
| Mr. Satish Varma | Executive Director |
| Ms. Anupama Datla Desai | Executive Director |
| Ms. Rajeshwari Datla | Non Executive Director |
| Mr. Pramod Kasat | Ind. Non-Executive Director |
| Ms. Rajashri Ojha | Ind. Non-Executive Director |
| Mr. Ramanand Mundkur | Independent Director |
FAQ
What is the intrinsic value of Fermenta Biotech Ltd?
Fermenta Biotech Ltd's intrinsic value (as of 18 December 2025) is 245.20 which is 29.94% lower the current market price of 350.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,030 Cr. market cap, FY2025-2026 high/low of 449/219, reserves of ₹376 Cr, and liabilities of 651 Cr.
What is the Market Cap of Fermenta Biotech Ltd?
The Market Cap of Fermenta Biotech Ltd is 1,030 Cr..
What is the current Stock Price of Fermenta Biotech Ltd as on 18 December 2025?
The current stock price of Fermenta Biotech Ltd as on 18 December 2025 is 350.
What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is 449/219.
What is the Stock P/E of Fermenta Biotech Ltd?
The Stock P/E of Fermenta Biotech Ltd is 9.19.
What is the Book Value of Fermenta Biotech Ltd?
The Book Value of Fermenta Biotech Ltd is 133.
What is the Dividend Yield of Fermenta Biotech Ltd?
The Dividend Yield of Fermenta Biotech Ltd is 0.71 %.
What is the ROCE of Fermenta Biotech Ltd?
The ROCE of Fermenta Biotech Ltd is 23.0 %.
What is the ROE of Fermenta Biotech Ltd?
The ROE of Fermenta Biotech Ltd is 24.9 %.
What is the Face Value of Fermenta Biotech Ltd?
The Face Value of Fermenta Biotech Ltd is 5.00.